Experimental drug TAK-243 targets Hard-to-Treat blood cancers

NCT ID NCT03816319

Terminated Disease control Sponsor: National Cancer Institute (NCI) Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 29 times

Summary

This early-stage trial tests the safety and best dose of TAK-243 in about 42 adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or are not responding to standard therapy. TAK-243 works by blocking enzymes that cancer cells need to grow. The study is currently suspended.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Moffitt Cancer Center

Tampa, Florida, 33612, United States
Northwestern University

Chicago, Illinois, 60611, United States
Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210, United States
University Health Network-Princess Margaret Hospital

Toronto, Ontario, M5G 2M9, Canada
VCU Massey Comprehensive Cancer Center

Richmond, Virginia, 23298, United States

Conditions

Explore the condition pages connected to this study.

MYELODYSPLASTIC SYNDROME WITH EXCESS BLASTS RECURRENT ACUTE MYELOID LEUKEMIA RECURRENT MYELODYSPLASTIC SYNDROME RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA REFRACTORY ACUTE MYELOID LEUKEMIA REFRACTORY MYELODYSPLASTIC SYNDROME REFRACTORY MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA